4th Quarter - Report

W STRATEGIES, LLC for ALEXION PHARMACEUTICALS

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Education and outreach to Congressional staff on coverage and reimbursement of drugs in the Republic of Korea. P.L. 112-41, The United States-Korea Free Trade Agreement Implementation Act.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR)

Health Issues HCR

Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to regulatory pathway for biosimilars and orphan drugs.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

H.R. 3630/H.R. 3765: Temporary Payroll Tax Cut Continuation Act of 2011 as they related to Medicare reimbursement for Part B drugs. P.L. 112-25 - The Budget Control Act of 2011 as it relates to Medicare reimbursement for Part B drugs.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR)

Bills named: H.R. 3630 (112th), H.R. 3765 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.